Table 1.
Demographic and clinicopathological characteristics of the patients included in cohort study
| Characteristic |
BIM deletion status
|
All (N=140) |
|
|---|---|---|---|
| Heterozygous (N=37) |
Wild type (N=103) |
||
| Age (years) | |||
| Mean (SD) | 56.1 (11.05) | 58.5 (9.72) | 57.9 (10.11) |
| Median | 56.3 | 58.9 | 58.5 |
| <65 | 28 (75.7) | 75 (72.8) | 103 (73.6) |
| ≥65 | 9 (24.3) | 28 (27.2) | 37 (26.4) |
| Gender | |||
| Male | 8 (21.6) | 38 (36.9) | 46 (32.9) |
| Female | 29 (78.4) | 65 (63.1) | 94 (67.1) |
| Family history of lung cancer | |||
| No | 33 (89.2) | 84 (81.6) | 117 (83.6) |
| Yes | 4 (10.8) | 19 (18.4) | 23 (16.4) |
| Smoking | |||
| No | 30 (81.1) | 76 (73.8) | 106 (75.7) |
| Yes | 7 (18.9) | 27 (26.2) | 34 (24.3) |
| Radical surgery | |||
| No | 22 (59.5) | 74 (71.8) | 96 (68.6) |
| Yes | 15 (40.5) | 29 (28.2) | 44 (31.4) |
| ECOG performance status | |||
| 0 | 4 (10.8) | 6 (5.8) | 10 (7.1) |
| 1 | 29 (78.4) | 92 (89.3) | 121 (86.4) |
| 2 | 4 (10.8) | 5 (4.9) | 9 (6.4) |
| Histology | |||
| Adenocarcinoma | 33 (89.2) | 95 (92.2) | 128 (91.4) |
| Other | 4 (10.8) | 8 (7.8) | 12 (8.6) |
| Number of metastatic organs* | |||
| ≤2 | 26 (70.3) | 68 (66.7) | 94 (67.6) |
| >2 | 11 (29.7) | 34 (33.3) | 45 (32.4) |
| EGFR mutation | |||
| 18 mutation | 1 (2.7) | 3 (2.9) | 4 (2.9) |
| 19 mutation | 22 (59.5) | 51 (49.5) | 73 (52.1) |
| 20 mutation | 2 (5.4) | 2 (1.9) | 4 (2.9) |
| 21 mutation | 12 (32.4) | 47 (45.6) | 59 (42.1) |
| Clinical stage | |||
| III | 4 (10.8) | 5 (4.9) | 9 (5.4) |
| IV | 33 (89.2) | 98 (95.1) | 131 (93.6) |
| EGFR-TKIs treatment | |||
| First line | 12 (32.4) | 42 (40.8) | 54 (38.6) |
| Second or more line | 25 (67.6) | 61 (59.2) | 86 (61.4) |
Notes: Data presented as n (%) unless stated otherwise.
*
Data missing for one patient.
Abbreviations: ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; TKIs, tyrosine kinase inhibitors; SD, standard deviation.